Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

Weersink, Rianne A.; Timmermans, Lotte; Monster-Simons, Margje H.; Mol, Peter G. M.; Metselaar, Herold J.; Borgsteede, Sander D.; Taxis, Katja

Published in:
Frontiers in Pharmacology

DOI:
10.3389/fphar.2019.01031

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Weersink, R. A., Timmermans, L., Monster-Simons, M. H., Mol, P. G. M., Metselaar, H. J., Borgsteede, S. D., & Taxis, K. (2019). Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment. Frontiers in Pharmacology, 10, Article 1031. https://doi.org/10.3389/fphar.2019.01031

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

Rianne A. Weersink1,2,*, Lotte Timmermans1,3,†, Margje H. Monster-Simons4,5, Peter G. M. Mol4,5, Herold J. Metselaar6, Sander D. Borgsteede2,7 and Katja Taxis1

1 Unit of Pharmacotherapy, Epidemiology & Economics, Department of Pharmacy, University of Groningen, Groningen, Netherlands, 2 Department of Clinical Decision Support, Health Base Foundation, Houten, Netherlands, 3 Department of Pharmaceutical and Pharmacological Sciences, Unit of Clinical Pharmacology and Pharmacotherapy, Catholic University of Leuven, Leuven, Belgium, 4 Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, Netherlands, 5 Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 6 Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, Netherlands, 7 Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands

Background: In 2005, the European Medicines Agency (EMA) released guidance on pharmacokinetic studies in patients with hepatic impairment. This guidance describes the design of these studies and what information should be presented in the Summary of Product Characteristics (SmPC). We aim to evaluate the availability and clinical applicability of information on medicine use in patients with hepatic impairment in SmPCs and registrational dossiers of recently approved medicines.

Methods: We reviewed SmPC information on use in patients with hepatic impairment of 51 new medicines authorized between 2015 and 2017. Per medicine, we assessed the availability of nine information items derived from the EMA guidance, i.e. type of hepatic disease studied; stratification by severity of hepatic impairment; influence of hepatic impairment on the pharmacokinetics; safety advice in mild, moderate, and severe hepatic impairments; and dosing recommendation in mild, moderate, and severe hepatic impairments. If unavailable, the European Public Assessment Report (EPAR) and study report were consulted consecutively. Of available items, clinical applicability was assessed by labeling information as “clear” or “ambiguous”.

Results: Of 51 medicines, 15 had no pharmacokinetic study in patients with hepatic impairment described in their SmPC. The other 36 SmPCs contained on average seven of the nine information items (range 4–9). One SmPC contained all 9 items, and after consulting, the study reports, 11 SmPCs were complete. The item “type of hepatic disease studied” was available in one SmPC, though it could be retrieved in 21 study reports. Regarding clinical applicability, there was no medicine with all information items available and clearly formulated in the SmPC. A total of 12 medicines (33%) contained only clearly formulated information, while 24 (67%) contained at least one ambiguously formulated information item.
INTRODUCTION

Patients with hepatic impairment are at risk for adverse drug reactions when using medicines as drug concentrations could increase due to pharmacokinetic (PK) changes (Delco et al., 2005; Verbeeck, 2008). The influence of hepatic impairment on the PK of a medicine depends on the type and severity of the underlying hepatic disease (Hughes, 2008; Verbeeck, 2008). Cirrhosis, the advanced stage of all chronic liver diseases, has the largest influence on drug concentrations (Ohnhaus et al., 1982; Morgan and McLean, 1995; Lil et al., 2000; Verbeeck, 2008). Research demonstrated that nearly 30% of patients with cirrhosis suffer from adverse drug reactions and that almost 80% of these reactions was possibly preventable because inadequate dosages or contraindicated medicines were used (Franz et al., 2013).

The knowledge on dose adjustments and contraindications for medicines in patients with hepatic impairment is often based on the results of PK studies conducted by pharmaceutical companies. Realizing that information was not always generated to the same extent for different medicines, the European Medicines Agency (EMA) published a guideline on the evaluation of PK in patients with hepatic impairment in 2005 (European Medicines Agency, 2005). This guideline provides recommendations on the design and reporting of PK studies in subjects with impaired hepatic function. The results from these PK studies are presented in a study report and discussed in the European Public Assessment Report (EPAR). In the Summary of Product Characteristics (SmPC), the safety and dosing recommendations resulting from the PK studies are presented to healthcare professionals.

Previous research indicated possible shortcomings in information provided in SmPCs on medication use in patients with hepatic impairment. A small study from 2002 reported that the advice in SmPCs was often inconsistent, unclear, and unhelpful (Anonymous, 2001). A more recent study (2013) evaluated prescribing guidance on patients with hepatic impairment in USA Food and Drug Administration (FDA)-approved labels and reported non-specific dose recommendations (Chang et al., 2013). No previous study has assessed the quality of prescribing information in SmPCs after release of the EMA guideline, nor in other authorization documents. Our aim is therefore to evaluate the availability of specific information on the use of a medicine in patients with hepatic impairment in SmPCs, EPARs, and study reports of recently approved medicines and to evaluate the clinical applicability of the SmPC information.

MATERIALS AND METHODS

We included all human medicines authorized through a centralized procedure by the EMA from 2015 until 2017 containing a new chemical entity. The EMA guideline recommends studies in patients with hepatic impairment if medicines are likely to be used in this population, and if hepatic impairment is likely to influence PK (European Medicines Agency, 2005). To focus our analysis on these medicines, we excluded single-use medicines (such as vaccines), non-systemic locally acting medicines, orphan medicines, and medicines that had a conditional approval or were approved under exceptional circumstances. Fixed-dose combination medicines were also excluded since these often contain one advice based on PK alterations and studies of two or more medicines which was difficult to incorporate in our method.

We used data from three different authorization documents: SmPCs, EPARs, and study reports. The SmPCs and EPARs were retrieved from the EMA website (https://www.ema.europa.eu) in April and May 2018. The versions of the documents available on this website correspond to the most recently updated version. Study reports are often not or only partially publicly available, and individual patient data (such as medical histories of study subjects) are also not (yet) published (European Medicines Agency, 2019). If available, study reports were accessed through the EMA’s clinical data website (https://clinicaldata.ema.europa.eu). The non-publicly available study reports and individual patient data were accessed at the Dutch Medicines Evaluation Board.

Per medicine, we examined the SmPC to assess whether a study in patients with hepatic impairment was conducted and described (Figure 1). If a study was described in the SmPC, the availability of the information and the clinical applicability were assessed. For medicines without a study in hepatic impairment, we assessed if this was explicitly mentioned in the SmPC and if a justification was given for its absence.

Assessment of Information Availability and Clinical Applicability

For the assessment of information availability, we used nine information items derived from the section about labeling of the EMA guideline (Table 1) (European Medicines Agency,
TABLE 1 | Content of section 5 “labeling issues” from the EMA guideline on the evaluation of pharmacokinetics in patients with hepatic impairment (European Medicines Agency, 2005).

“Specific dosing recommendations should be given in section 4.2 with cross-reference to section 5.2, and, when relevant, to sections 4.3 and/or 4.4. The characteristics of the subjects included in the hepatic impairment study should be stated in section 4.2, and extrapolations should not be made beyond what has actually been studied. Efforts should be made to describe the change in pharmacokinetics related to changes in clinical parameters like S-albumin, S-bilirubin, or prothrombin time (preferably expressed in terms of the international normalized ratio, INR) if a relationship has been found. Even when no posology adjustment is needed, this should be stated in section 4.2.

Lack of information regarding influence of hepatic impairment on the pharmacokinetics could result in a contraindication or warning, depending on the characteristics of the drug. When precaution is recommended and no specific dose recommendations can be given, measures to be taken by the prescriber (e.g., careful monitoring) should be specified.

Information regarding the influence of hepatic impairment on the pharmacokinetics should be given in the special populations subsection of section 5.2, with cross-reference to section 4.2 if posology adjustment is needed and 4.5 if interactions may be changed. The information should include which type of hepatic disease has been studied, effects on parent compound and metabolites and, when relevant, include effects on protein binding and unbound exposure.

Also when pharmacokinetics in patients with hepatic impairment has not been evaluated, this information should be given in section 5.2. When relevant, information that hepatic impairment is unlikely to affect the pharmacokinetics to a clinically relevant extent could be included if this has been well justified.” (European Medicines Agency, 2005).

Analyses
Two authors (LT, RW) evaluated the availability and clinical applicability of information in the SmPCs and EPARs and discussed in case of discrepancies. If the authors still disagreed, a discussion was held with two other researchers (MM-S, KT) until consensus was reached. RW examined the study reports together with an employee of the Dutch Medicines Evaluation Board (MM-S). The results were analyzed using Microsoft Excel and reported with descriptive statistics.

RESULTS
From 2015 until 2017, the EMA authorized a total of 258 new human medicines, and 101 were new chemical entities (Figure 2). We included 51 medicines in our study (Table 3).
With 27 (53%) of these, a dedicated PK study was conducted in patients with hepatic impairment. For nine medicines (18%), the SmPC described a population PK analysis, and for three of these nine, a dedicated PK study is currently ongoing or recently finished.

For 15 (29%) included medicines, no study was performed to assess the impact of hepatic impairment on the PK. Thirteen of these were monoclonal antibodies or other medicines not metabolized or eliminated by the liver. The remaining two are partly excreted in feces and have no ongoing dedicated PK study. Eleven of these 15 medicines also described in the SmPC that no study was performed, and eight provided a justification for the absence of a hepatic impairment study.

TABLE 2 | Method used for assessing the availability and clinical applicability of information in SmPCs.

| No. | Assessment of availability | Description | Example sentences |
|-----|----------------------------|-------------|-------------------|
| 1. | Characteristics of patients | Type of hepatic disease studied | Is the patient group clearly described? Is the term “hepatic impairment” defined? | “Patients with cirrhosis” |
| 2. | | Stratification by severity of hepatic impairment | Are the terms used to grade the severity of hepatic impairment defined? | “Mild hepatic impairment (Child–Pugh A)” |
| | Influence on pharmacokinetics | | Clinical applicability not tested |
| 3. | | Influence of hepatic impairment on the pharmacokinetics |
| | Safety recommendations | Advice on safety in patients with: | Clear statement that medicines can or cannot be used or which safety actions are neededa | “Contraindicated,” “use with caution while monitoring …,” “dose adjustment (not) needed” |
| | | Mild hepatic impairment | “Use with caution,” “it is preferable to,” “not recommended to use” |
| | | Moderate hepatic impairment |
| | | Severe hepatic impairment |
| | Dosing recommendations | Dosing recommendations in patients with: | Specified dose adjustment or stating that no dose adjustments are necessarya | “Adjust dose to 500 mg once daily,” “no dose adjustment is necessary,” “contraindication” |
| | | Mild hepatic impairment |
| | | Moderate hepatic impairment |
| | | Severe hepatic impairment |

aThese items were assessed for every severity class (i.e., mild, moderate, and severe).

TABLE 3 | Characteristics of the included medicines (n = 51).

| Year of authorization | n | % |
|-----------------------|---|---|
| 2015                  | 20 | 39 |
| 2016                  | 15 | 29 |
| 2017                  | 16 | 31 |

| Therapeutic area | n | % |
|------------------|---|---|
| Alimentary tract and metabolism | 2 | 4 |
| Blood and blood forming organs | 7 | 14 |
| Cardiovascular system | 3 | 6 |
| Dermatological drugs | 1 | 2 |
| Genitourinary system and reproductive hormones | 1 | 2 |
| Systemic hormonal preparations | 1 | 2 |
| Antifungal agents | 5 | 10 |
| Antineoplastic and immunomodulating agents | 24 | 47 |
| Musculoskeletal system | 1 | 2 |
| Nervous system | 4 | 8 |
| Respiratory system | 2 | 4 |

| Study in patients with hepatic impairment | n | % |
|------------------------------------------|---|---|
| Dedicated pharmacokinetic study | 27 | 53 |
| Population pharmacokinetic analysis | 9 | 18 |
| No study | 15 | 29 |
| Total | 51 | 100 |

FIGURE 2 | Flowchart of inclusion of medicines. EMA, European Medicines Agency.
TABLE 4 | Availability of information on patients with hepatic impairment in authorization documents of 36 medicines.

| Information item                                      | SmPC          | EPAR          | Study report |
|------------------------------------------------------|---------------|---------------|--------------|
|                                                      | n  | %   | n  | %   | n  | %   |
| Type of hepatic disease studied                      |    |     |    |     |    |     |
| Stratification by severity of hepatic impairment      | 1  | 3   | 1  | 3   | 22 | 61  |
| Influence of hepatic impairment on the pharmacokinetics | 35 | 97  | 35 | 97  | 35 | 97  |
| Safety advice in mild hepatic impairment              | 36 | 100 | 36 | 100 | 36 | 100 |
| Safety advice in moderate hepatic impairment          | 36 | 100 | 36 | 100 | 36 | 100 |
| Safety advice in severe hepatic impairment            | 36 | 100 | 36 | 100 | 36 | 100 |
| Dosing recommendation in mild hepatic impairment      | 36 | 100 | 36 | 100 | 36 | 100 |
| Dosing recommendation in moderate hepatic impairment  | 28 | 78  | 28 | 78  | 30 | 83  |
| Dosing recommendation in severe hepatic impairment    | 16 | 44  | 17 | 47  | 17 | 47  |

Results are expressed in number and percentage of medicines with the information item available after consulting the SmPC, EPAR, or study report. The additional information from the study reports in terms of type of hepatic disease studied can be found in Table 5 and the dosing recommendations in moderate hepatic impairment in the published studies of these medicines (Khatri et al., 2015; Gibbs et al., 2017). EPAR, European Public Assessment Report; SmPC, Summary of Product Characteristics.

TABLE 5 | Overview of hepatic diseases documented in the medical history of the included patients in the study reports of 21 medicines. Expressed in number of patients and stratified by severity of impairment and documentation of cirrhosis.

| Documented hepatic disease | Totala (n = 368) | Mild hepatic impairment (n = 115) | Moderate hepatic impairment (n = 166) | Severe hepatic impairment (n = 57) |
|---------------------------|------------------|----------------------------------|--------------------------------------|----------------------------------|
|                           | n   | %   | n   | %   | n   | %   | n   | %   |
| Cirrhosis, totalb         | 264 | 71.7 | 68  | 59.1 | 139 | 83.7 | 43  | 75.4 |
| Alcohol liver disease     | 109 | 41.3 | 24  | 35.3 | 72  | 51.8 | 15  | 34.9 |
| Viral hepatitis C          | 139 | 52.7 | 39  | 57.4 | 11  | 7.9  | 2   | 4.7  |
| Viral hepatitis B          | 23  | 8.7  | 7   | 10.3 | 2   | 1.4  | 1   | 2.3  |
| NASH                      | 6   | 2.3  | 3   | 4.4  | 6   | 4.3  | 5   | 11.6 |
| Other                     | 15  | 5.7  | 4   | 5.9  | 6   | 4.3  | 5   | 11.6 |
| Unknown                   | 26  | 9.8  | 2   | 2.9  | 16  | 11.5 | 5   | 11.6 |
| No cirrhosis documented, totalb | 104 | 28.3 | 47  | 40.9 | 27  | 16.3 | 14  | 24.6 |
| Alcohol liver disease     | 24  | 23.1 | 10  | 21.3 | 8   | 29.6 | 2   | 14.3 |
| Viral hepatitis C          | 59  | 56.7 | 34  | 72.3 | 12  | 44.4 | 11  | 78.6 |
| Viral hepatitis B          | 6   | 5.8  | 0   | 0.0  | 5   | 18.5 | 1   | 7.1  |
| NASH                      | 8   | 7.7  | 4   | 8.5  | 3   | 11.1 | 1   | 7.1  |
| Other                     | 17  | 18.3 | 5   | 10.6 | 6   | 22.2 | 1   | 7.1  |
| Unknown                   | 7   | 6.7  | 2   | 4.3  | 0   | 0.0  | 0   | 0.0  |

aThe total number of patients contains data from one additional medicine. The medical history of this medicine was not stratified by severity of impairment.
bThe individual hepatic diseases do not sum up to the total number because patients could have more than one hepatic disease documented.
NASH: non-alcoholic steatohepatitis.

Availability of Information

Of the 36 medicines with a PK study, the SmPCs contained on average 7 of the 9 information items (range 4–9). The items “influence of hepatic impairment on the pharmacokinetics,” “safety advice in mild hepatic impairment,” and “dosing recommendation in mild hepatic impairment” were found in the SmPCs of all of these 36 medicines (Table 4). Low scoring items were “the type of hepatic disease studied” (n = 1, 3%) and “dosing recommendation in severe hepatic impairment” (n = 16, 44%). The number of medicines with all nine information items available increased from one (3%) after the SmPC and EPAR evaluation, to 11 (31%) medicines after consulting the study report. Of all the study reports consulted (n = 35), 10 (29%) were publicly available on the EMA website.

The SmPC of one medicine described the type of hepatic disease studied which was cirrhosis. This information was available though in 21 study reports. Table 5 provides an overview of the hepatic diseases documented in these study reports. For five medicines, all patients included in the study had cirrhosis documented in their medical history. For the other medicines, and especially in the mild hepatic impairment group, the medical history of the included patients described a variety of hepatic diseases with and without cirrhosis. In some medical histories, we could not find a (chronic) liver disease documented.

The SmPCs of 35 (97%) medicines stratified hepatic impairment by severity with 27 describing the use of the Child–Pugh classification (all dedicated PK studies). All of these 27 medicines included patients with moderate hepatic impairment.
(Child–Pugh B) in their PK study, 25 included patients with mild hepatic impairment (Child–Pugh A), and 14 severe hepatic impairment patients (Child–Pugh C). The remaining eight medicines stratified the severity of hepatic impairment by the National Cancer Institute (NCI) criteria of hepatic dysfunction (all population PK analyses). All eight included patients with NCI mild hepatic impairment in their study, one included patients with NCI moderate hepatic impairment, and none patients with NCI severe hepatic impairment.

Table 6 gives an overview of the content of the safety and dosing recommendations, stratified by severity of hepatic impairment. Contraindications and dose adjustments were only advised in medicines subjected to a dedicated PK study.

### Clinical Applicability of Information

Figure 3 shows the clinical applicability assessment of the SmPC information of the 36 medicines with a PK study. Table 7 provides examples of clear and ambiguous information in SmPCs. When available, dosing recommendations were almost always formulated clearly, while information on the definition of mild/moderate/severe hepatic impairment (20 clear SmPCs, 56%) and the safety advice in severe hepatic impairment (14 clear SmPCs, 39%) was often ambiguously formulated. The type of hepatic disease studied was only present in one SmPC but ambiguously formulated. Four different wordings were used interchangeably (hepatic impairment, chronic liver disease, pre-existing hepatic impairment, and hepatic cirrhosis) to define the “at-risk population” (Table 7). There was no medicine with all information items available and clearly formulated. A total of 12 medicines (33%) contained only clearly formulated information, while 24 (67%) contained at least one ambiguously formulated information item (range 0–4).

### DISCUSSION

In this study, we reviewed SmPC information on patients with hepatic impairment of 51 recently approved medicines and found that 36 described a PK study in patients with hepatic impairment in their SmPC. On average, 7 of 9 information items requested by the EMA were available in these SmPCs. Yet, safety advice or dose recommendations for patients with severe hepatic impairment were unavailable for almost 60% of evaluated medicines and/or ambiguously formulated. Essential information on the type of hepatic disease of patients included in the required PK studies was lacking for 35 of 36 medicines but could be retrieved for 21 medicines in the non-publicly available part of the study report. Based on the documentation in the study reports, we could not confirm that the appropriate patients were studied in all PK studies. In addition, in more than 40% of evaluated medicines, the severity of hepatic impairment of the studied patients was not clearly specified in the SmPC.

A substantial part of information requested in the EMA guideline was available in the SmPCs of the medicines in our sample that conducted a PK study. For the other medicines, the lack of a hepatic impairment study was often justified by negligible hepatic clearance of the particular medicinal product which is accepted by the EMA (European Medicines Agency, 2005). Two earlier studies found different results. A study from 2001 showed that only a few of the 25 studied SmPCs gave specific, detailed advice on the use of a medicine in patients with hepatic impairment (Anonymous, 2001). Chang and colleagues (Chang et al., 2013) observed that a large part of FDA labels provided dosing recommendations, but these recommendations were in 60% of labels not stratified by severity of hepatic impairment while almost all SmPCs in our sample did so. This may be explained by different requirements between regulatory agencies, and differences between US and EU labelings on hepatic impairment have been previously noted (Björnsson et al., 2015). Considering though that applicants usually conduct a single PK study in patients with hepatic impairment that is submitted to all regulatory authorities, it is more likely that the enhanced information in SmPCs is explained by an improvement in the quality of information over time, as these earlier included medicines were approved before March 2001, respectively 2011.
TABLE 7 | Results of the assessment of the clinical applicability of the information: examples of clear and ambiguous information described in SmPCs concerning the use in patients with hepatic impairment.

| Clearly formulated information | Ambiguously formulated information |
|---------------------------------|-----------------------------------|
| **Patient characteristics**     |                                   |
| All terms to grade severity of hepatic impairment are defined: "Section 4.2: No dose adjustment is required in patients with mild hepatic impairment (Child–Pugh A). The dose should be reduced to 5 mg once daily in patients with moderate hepatic impairment (Child–Pugh B) (see sections 4.4 and 5.2)." Tofacitinib should not be used in patients with severe hepatic impairment (Child–Pugh C) (see section 4.3).” (Pfizer Ltd, 2017) | Ambiguous information on type of hepatic disease because of all the different terms used, no clear definition: “Section 4.2: Exposure to brivaracetam was increased in adult patients with chronic liver disease. (...) A maximum daily dose of 150 mg administered in two divided doses is recommended for all stages of hepatic impairment. (…) Section 4.4: There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are recommended for patients with hepatic impairment. Section 5.2: A pharmacokinetic study in subjects with hepatic cirrhosis (Child–Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50, 57, and 59%), relative to matched healthy controls.” (UCB Pharma SA, 2016) |
| Definition lacking of terms to stratify severity of impairment: "Section 4.2: No dose adjustment is required in patients with mild or moderate hepatic impairment. Baricitinib is not recommended for use in patients with severe hepatic impairment. Section 5.2: There was no clinically relevant effect on the PK of baricitinib in patients with mild or moderate hepatic impairment. The use of baricitinib has not been studied in patients with severe hepatic impairment.” (Eli Lilly, 2017) | Safety advice in patients with mild/moderate/severe hepatic impairment
Caution is explained: "There are no data in patients with severe hepatic impairment (see section 5.2). Rolapitant should be used with caution in these patients. If use cannot be avoided, patients should be monitored for adverse reactions to rolapitant (see section 4.8)." (Tesaro UK Ltd, 2017) |
| Safety advice in patients with mild/moderate/severe hepatic impairment
Ambiguous safety advice in moderate and severe hepatic impairment: "No dose adjustment of dasabuvir is required in patients with mild hepatic impairment (Child–Pugh A). Dasabuvir is not recommended in patients with moderate hepatic impairment (Child–Pugh B) (see sections 4.4 and 4.8). Dasabuvir should not be used in patients with severe hepatic impairment (Child–Pugh C) (see section 5.2)." (AbbVie Ltd, 2015) | Dosing recommendation in patients with mild/moderate/severe hepatic impairment
Concrete dose recommendation in moderate hepatic impairment lacking: "Section 4.2: No dose adjustment is necessary in patients with mild hepatic impairment (Child–Pugh Class A). There is limited clinical experience in patients with moderate hepatic impairment (Child–Pugh Class B). Caution must be exercised in these patients and dose adjustment may be necessary (see section 5.2). There is no clinical experience in patients with severe hepatic impairment (Child–Pugh Class C); therefore, olicapine is not recommended in these patients (see section 5.2).” (Bial - Portela and Ca SA, 2016) |

For clarity, brand names have been replaced by generic medicines names in all examples.
Prescribing information about patients with severe hepatic impairment was often lacking or ambiguously formulated. This was probably caused by a lack of clinical data: in the PK study of only 14 medicines, patients with severe hepatic impairment were included. Previous studies also showed that, with increasing severity of hepatic impairment, less prescribing information is available (Periáñez-Párraga et al., 2012; Chang et al., 2013). If information on patients with severe hepatic impairment was available, it was frequently ambiguously formulated. Vague statements such as “not recommended to use” leave it open for interpretation whether the medicine is absolutely contraindicated and what would be the circumstances of usage. Ambiguous formulations such as “use with caution,” “not recommended to use,” and “should not be used” were also observed in studies examining SmPC recommendations in other clinical areas such as renal impairment (Geerts et al., 2012; Beers et al., 2013; Salgado et al., 2013; Arguello et al., 2015). This finding should be seen in the light of the ethical and practical difficulties faced with research in such a vulnerable patient group. Yet, although no clinical data are available, measures to be taken by the prescriber could still be specified or explained in the SmPC (see Table 7, example with rolapitant) as also advised by the EMA (European Medicines Agency, 2005).

Another important finding was that the type of hepatic disease of patients included in PK studies was not specified in the SmPC text, even though specifically requested by the EMA guideline (European Medicines Agency, 2005). As shown in literature, prescribers other than gastroenterologists often do not know which patients with a liver disease need dose adjustments or avoidance of certain medicines (Rossi et al., 2008; Nguyen et al., 2014) that is possibly caused by the use of the undefined term “hepatic impairment.” In the one medicine where the type of hepatic disease studied was available in the SmPC, the recommendations were ambiguous because different wordings were used interchangeably to define the “at-risk population.” The study from 2001 already concluded that this “at-risk population” was often vaguely described (Anonymous, 2001), so it seems little to no progress has been made in this area. We could find the information on the hepatic impairment that caused the impairment for most medicines in the study reports. But contrary to SmPCs and EPARs, most of these reports are not (yet) accessible to healthcare professionals. The EMA is trying to increase transparency by providing access to clinical study data on a website (European Medicines Agency, 2019); yet, we noticed we could only find study reports for 29% of the medicines. More importantly, it appears that regulators are not aware that the hepatic disease information is relevant to the healthcare professionals. We recommend to include this information in the SmPCs.

The FDA label study (Chang et al., 2013) described the explicit use of standardized terminology such as the Child–Pugh score as solution for the non-specific phrase “hepatic impairment.” In our sample, all dedicated PK studies used this score. An important remark to the Child–Pugh classification is that it was not intended and validated as a measure to assess the remaining capacity of the liver to eliminate medicines (European Medicines Agency, 2005). As the guideline also recommends, appropriate use of the Child–Pugh classification is important because the parameters are not specific of hepatic (elimination) impairment (Durand and Valla, 2005; European Medicines Agency, 2005). For example, everyone scores 5 points (i.e., class A: “mild hepatic impairment”) because that is the minimum score and increases in one of the parameters due to other causes (e.g., a bilirubin increase due to hemolysis or a prolonged INR due to coumarin use) could even result in a “moderate hepatic impairment” classification. The guideline provides no further details on appropriate use; however, in clinical practice, the Child–Pugh score is intended to assess the severity and prognosis of cirrhosis (Pugh et al., 1973; Durand and Valla, 2005). Prior literature also concluded that hepatic elimination was not significantly impaired in a variety of chronic liver diseases unless cirrhosis was present (Morgan and McLean, 1995; Verbeeck, 2008). Based on the data we found in the study reports, we cannot confirm that the Child–Pugh classification was used appropriately in all studies. Most of the subjects in the PK studies had documented cirrhosis, and the Child–Pugh classification was used as intended. In the remaining subjects, insufficient details were provided to assess if the hepatic elimination capacity was relevantly impaired because there was no cirrhosis documented and not even a (chronic) liver disease for some. Inappropriate use of the Child–Pugh classification in clinical studies may result in an underestimation of the changes in PK in patients with hepatic impairment due to cirrhosis. Because of its limitations, in further research, alternatives for the Child–Pugh classification should be explored.

**Strengths and Limitations**

We performed an in-depth analysis of the hepatic impairment information in authorization documents. Unique to our study is the access we had to the non-publicly available part of the study reports. We studied a limited number of medicines, making comparisons between therapeutic groups or between SmPC information over time not possible. Hence, our results cannot be generalized to older medicines, especially not those authorized before publication of the guideline in 2005. Furthermore, we only studied medicines that were granted market authorization via a centralized procedure, so results are not necessarily valid for medicines authorized through a national or decentralized procedure. Nevertheless, in national and decentralized procedures, use of the EMA guidelines is also recommended.

**Implications**

The lack of clear guidance in SmPCs on patients with severe hepatic impairment can be challenging for healthcare professionals treating these severely ill patients who need medicines but are very sensitive to PK and pharmacodynamic alterations. As there are practical and ethical issues involved in conducting pre-registration studies in patients with severe hepatic impairment, it would be helpful to collect post-marketing data. Further research could explore the potential of registries as information source on treatment and outcome in that patient group.

The EMA reinforced in their hepatic impairment guideline the need for further research to strengthen and improve the guideline (European Medicines Agency, 2005). We recommend to update
the guideline on three points. First, the guideline must mention that all terms used to describe the severity of hepatic impairment in the SmPC should also be defined [e.g., patients with mild hepatic impairment (Child–Pugh A)]. Although these definitions are easy to include, more than 40% of SmPCs did not provide this information. Second, the guideline describes that if precautionary use of a medicine is advised, SmPCs should also specify measures to be taken by the prescriber (European Medicines Agency, 2005). Nevertheless, we noticed a high prevalence of ambiguous safety advice that lacked such specifications. Therefore, this should be better expressed in the guideline and perhaps also better monitored by the regulators. Finally, we showed that the main weakness of the guideline is the vague term “hepatic impairment” that leaves room for interpretation. Pharmaceutical companies and regulators interpret this differently resulting in a diversity of patient populations in the PK studies. Healthcare professionals as well can have difficulties to interpret “hepatic impairment,” possibly resulting in non-optimal advice, under- or overdosing. As there is no generally accepted definition for the term “hepatic impairment,” its use is not helpful in clinical practice (Bjornsson et al., 2015). Therefore, the EMA guideline needs to be updated to include a more precise definition. Perhaps, it is even better not to use the ambiguous term “hepatic impairment” anymore. Instead, we recommend to use the clearly defined term “liver cirrhosis” in authorization documents, but also in online drug reference works and in the published PK studies. These activities may prevent prescribing problems in practice, such as the use of inadequate dosages or contraindicated drugs in patients with cirrhosis, as demonstrated by Franz et al. (Franz et al., 2013). In the Netherlands, the drug-disease interaction “hepatic impairment” has been replaced in clinical decision support systems by a new drug-disease interaction “liver cirrhosis” to better support healthcare professionals (Weersink et al., 2016; Weersink et al., 2018).

CONCLUSION

In this study, we have shown that SmPCs of recently approved medicines contain a large part of the information required by the EMA guideline on patients with hepatic impairment. Although available, the safety advice was often ambiguously formulated and therefore not per se clinically applicable. Unclear advice on patients with severe hepatic impairment was often explained by a lack of research. Information on the type of hepatic disease was often lacking in the SmPC but could be found in the non-publicly available part of the study report. We recommend that such information should be included in SmPCs. This information is also needed to judge if the Child–Pugh classification was used appropriately, because the parameters it includes are not specific of hepatic (elimination) impairment. Based on our results, we cannot conclude that the appropriate patients were studied in all hepatic impairment studies. We specifically recommend to update the 2005 EMA guideline to use the clearly defined term “liver cirrhosis” instead of “hepatic impairment”. This will support pharmaceutical companies in conducting and reporting PK studies in the most relevant patients with hepatic disease and healthcare professionals when prescribing for these vulnerable patients.

DATA AVAILABILITY

The dataset used in these analyses are available upon request to interested researchers. The SmPCs and EPARs assessed in this study are publicly available on the website of the EMA (https://www.ema.europa.eu). The evaluated clinical study reports are not publicly available and cannot be supplied because of confidentiality. Requests to access these reports should be directed to the Marketing Authorization Holder.

AUTHOR CONTRIBUTIONS

RW, LT, MM-S and KT participated in data analysis and interpretation. RW and LT drafted the manuscript. MM-S, KT, PM, HM and SB critically revised the manuscript. Supervision was done by KT and MM-S. All authors approved the final version of the manuscript.

FUNDING

This study was funded by the Dutch Medicines Evaluation Board (CBG-MEB).

REFERENCES

AbbVie Ltd. (2015) Summary of Product Characteristics: Exviera (dasabuvir). Maidenhead, United Kingdom.
Anonymous (2001). Failings in treatment advice, SPCs and black triangles. Drug Ther. Bull. 39, 25–27. doi: 10.1136/db.2001.39425
Arguello, B., Salgado, T. M., and Fernandez-Llimos, F. (2015). Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactation. Br. J. Clin. Pharmacol. 79, 537–544. doi: 10.1111/bcp.12515
Beers, E., Egberts, T. C. G., Leutkens, H. G. M., and Jansen, P. A. F. (2013). Information for Adequate Prescribing to Older Patients. Drugs Aging 30, 255–262. doi: 10.1007/s40266-013-0059-y
Bial - Portela, and Ca, S.A. (2016). Summary of Product Characteristics: Ongentys (opicapone). São Mamede do Coronado, Portugal.
Bjornsson, E. S., Jacobsen, E. I., Einarsdottir, R., and Chalasani, N. (2015). Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology 148, 269–273. doi: 10.1053/j.gastro.2014.12.007
Chang, Y., Burckart, G. J., Lesko, L. J., and Dowling, T. C. (2013). Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J. Clin. Pharmacol. 53, 962–966. doi: 10.1002/jcph.128
Delco, E., Tchambaz, L., Schilenger, R., Drewe, J., and Krähenbühl, S. (2005). Dose adjustment in patients with liver disease. Drug Saf. 28, 529–545. doi: 10.2165/00002018-200528060-00005
Durand, F., and Valla, D. (2005). Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J. Hepatol. 42, S107. doi: 10.1016/j.jhep.2004.11.015
Eli Lilly (2017). Summary of Product Characteristics: Olumiant (baricitinib). Utrecht, the Netherlands.
European Medicines Agency. (2019) Clinical data available. July [online]. Available: https://clinicaldata.ema.europa.eu/web/cdp/background (last accessed: 4 July).

European Medicines Agency. 2005 Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. February 2005 [online]. Available: https://www.ema.europa.eu/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf (last accessed: 21 February 2019).

Franz, C. C., Hildbrand, C., Born, C., Egger, S., Bravo, A. E. R., and Krähenbühl, S. (2013). Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur. J. Clin. Pharmacol. 69, 1565–1573. doi: 10.1007/s00228-013-1502-z

Geerts, A. F. J., De Koning, F. H. P., Van Solinge, W. W., De Smet, P. A. G., M., and Egberts, T. C. G. (2012). Instructions on laboratory monitoring in 200 drug labels. Clin. Chem Lab. Med. 50, 1351–1358. doi: 10.1515/cclm-2011-0753

Hughes, C. (2008). “Assessing liver function,” in Drugs and the liver. Ed. P. North-Lewis (London: Pharmaceutical Press), 73–99.

Khatri, A., Menon, R. M., Marbury, T. C., Lawitz, E. J., Podsadecki, T. J., Mullally, V. M., et al. (2015). Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J. Hepatol. 63 (4), 805–812. doi: 10.1016/j.jhep.2015.05.029

Lill, J. S., O’Sullivan, T., Bauer, L. A., Horn, J. H., Carithers, J. R., Strandness, D. E., et al. (2000). Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. J. Clin. Pharmacol. 40, 250–257. doi: 10.1177/00003991002008919

Morgan, D. J., and McLean, A. I. (1995). Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin. Pharmacokinet. 29, 370–391. doi: 10.2165/00003088-199529050-00005

Nguyen, D., Banerjee, N., Abdelaziz, D., and Lewis, J. (2014). Trainees’ attitudes and preferences toward the use of over the counter analgesics in patients with chronic liver disease. Drug Saf. 63, 261–270. doi: 10.2165/00002018-200831030-00007

Saltz, S. M., Argello, B., Martinez-Martinez, F., Benrimoj, S. L., and Fernandez-Llimos, F. (2013). Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment. Eur. J. Clin. Pharmacol. 69, 1973–1979. doi: 10.1007/s00228-013-1560-2

Tesaro UK Ltd. (2017). Summary of Product Characteristics: Varuby (rolapitant). London, United Kingdom.

UCB Pharma SA. (2016). Summary of Product Characteristics: Briviact (brivaracetam). Bruxelles, Belgium.

Verbeek, R. K. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol. 64, 1147–1161. doi: 10.1007/s00228-008-0553-z

Weersink, R. A., Bouma, M., Burger, D. M., Drenth, J. P. H., Hunfeld, N. G. M., Kranenborg, M., et al. (2016). Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open 6, e012991. doi: 10.1136/bmjopen-2016-012991

Weersink, R. A., Bouma, M., Burger, D. M., Drenth, J., P. H., Hunfeld, N. G. M., Kranebrough, M., et al. (2018). Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf. 41, 603–613. doi: 10.1007/s40264-017-0635-x

Copyright © 2019 Weersink, Timmermans, Monster-Simons, Mol, Metselaar, Borgsteede and Taxis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.